Cambrex Doubles cGMP Liquid Filling Capacity at its Mirabel, Québec Facility
March 26 2019 - 8:00AM
Cambrex Corporation (NYSE: CBM), the leading small molecule company
providing drug substance, drug product and analytical services
across the entire drug lifecycle, today announced it will double
the liquid packaging capacity and weekly output at its Mirabel,
Québec site in Canada with the addition of a cGMP packaging line
and a new filler on the existing packaging line. By June 2019, the
monthly capacity will be 1.2 million bottles compared with
approximately 600,000 per month today.
The new cGMP liquid packaging line allows the
use of two fillers (XP and non-XP) working in parallel from process
development through to cGMP commercial production and will now
offer flexibility to accommodate ethanol and isopropanol-based
solutions, aqueous solutions, lotions or suspensions. A new vision
system has also been installed for online serialization.
“This investment effectively doubles the liquid
packaging capacity and weekly output at the site, while improving
production cycle time and providing greater flexibility to
customers,” said Maryse Laliberte, VP & General Manager,
Cambrex Mirabel. “By operating multiple liquid packaging lines that
utilize the same technology, we are able to improve reaction times
for our customers’ specific requirements and to support unexpected
increases in demand.”
The new cGMP packaging line is linked to the
existing storage tank to fill solution and suspension, and to
explosion proof ratings tanks to allow for fill solutions
containing 100% alcohol or peroxide. The next-generation automatic
inline, high precision filler machine will be in operation by June
2019.
Cambrex acquired the 226,000 sq. ft. Montreal
facility, formerly part of Halo Pharma, in September 2018. The
plant is dedicated to formulation development and finished dosage
manufacturing services and can accommodate a wide range of solid
and liquid drug product dosage forms, including suspensions and
solutions, non-sterile, semi-solids, lotions, creams, ointments and
suppositories. It can also support high volume and small batch
manufacturing and offers a variety of packaging services for
bottles, tubes and cartons.
About Cambrex
Cambrex is the leading small molecule company
that provides drug substance, drug product and analytical services
across the entire drug lifecycle. The company provides customers
with an end-to-end partnership for the research, development and
manufacture of small molecule therapeutics. With over 35 years’
experience and a growing team of over 2,000 experts servicing
global clients from sites in North America and Europe, Cambrex is a
trusted partner in branded and generic markets for API and dosage
form development and manufacturing.
Cambrex offers a range of specialist drug
substance technologies and capabilities including biocatalysis,
continuous flow, controlled substances, solid state science,
material characterization and highly potent APIs. In addition,
Cambrex can support conventional dosage forms including oral
solids, semi-solids and liquids and has the expertise to
manufacture specialist dosage forms such as modified-release, fixed
dose combination, pediatric, bi-layer tablets, stick packs,
topicals, controlled substances, sterile and non-sterile
ointments.
For more information, please visit
www.cambrex.com
Contact: Alex MawDirector, Marketing and CommunicationsTel: +44
7803 443 155Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Jul 2023 to Jul 2024